SAN DIEGO -- A novel drug significantly reduced IgA nephropathy-related proteinuria, according to interim findings of the ALIGN study. In the phase III trial, among 270 patients with the rare kidney ...
2023 should be a year of progress on kidney disease, with multiple catalysts lined up from multiple companies. Chinook Therapeutics, Inc. has the best risk-reward based on: i) valuation; ii) diversity ...
In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demonstrated a statistically significant 36.1% proteinuria (protein in urine) reduction ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback